10-Q: vTv Therapeutics Q2 Loss Widens Amid Cadisegliatin Trial Restart

vTv Therapeutics Inc. reported an increased net loss in the second quarter of 2025, driven by higher research and development expenses, as it reinitiates its pivotal Phase 3 CATT1 trial for cadisegliatin in Type 1 diabetes.

Summary

• Net loss attributable to vTv Therapeutics Inc. increased to $6.046 million for the three months ended June 30, 2025, compared to $5.180 million for the same period in 2024.
• For the six months ended June 30, 2025, net loss attributable to vTv Therapeutics Inc. was $11.138 million, up from $10.045 million in the prior year period.
• Research and development expenses rose by 19.3% to $4.103 million in Q2 2025, primarily due to increased payroll-related indirect costs.
• Cash and cash equivalents decreased to $25.922 million as of June 30, 2025, from $36.746 million at December 31, 2024.
• The Phase 3 CATT1 clinical trial for cadisegliatin in Type 1 diabetes reinitiated patient screening in May 2025, with the first subject randomized in August 2025.
• Top-line data from the CATT1 study is now expected in the second half of 2026, following a protocol amendment to shorten the trial duration from 12 to 6 months.
• The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025, after the company provided a complete response regarding a chromatographic signal.
• The company continues to evaluate financing strategies to increase cash reserves, including direct equity investments and potential licensing of other programs.

Sentiment

Score: 4

Explanation: The company faces significant financial challenges, including increasing losses and a 'going concern' warning, with a substantial accumulated deficit. While the lead clinical program, cadisegliatin, is progressing with the reinitiation of its Phase 3 trial and a positive patent development, the failure to secure a $20 million upfront payment and the continued reliance on future capital raises for operations indicate a precarious financial position. The positive clinical progress is overshadowed by the immediate liquidity concerns.

Positives

• FDA removed the clinical hold on the cadisegliatin program on March 14, 2025, allowing the Phase 3 CATT1 trial to reinitiate.
• Patient screening for the Phase 3 CATT1 trial reinitiated in May 2025, and the first subject was randomized on August 6, 2025, indicating progress in the lead program.
• The U.S. Patent and Trademark Office allowed claims covering the crystalline salt form of cadisegliatin in August 2025, strengthening the intellectual property portfolio.
• The protocol amendment to shorten the CATT1 study duration from 12 months to 6 months could expedite data availability.
• Cadisegliatin holds Breakthrough Therapy designation from the FDA for Type 1 Diabetes, which can expedite development and review.

Negatives

• Net loss attributable to vTv Therapeutics Inc. increased to $6.046 million for Q2 2025 from $5.180 million for Q2 2024.
• Net loss attributable to vTv Therapeutics Inc. increased to $11.138 million for H1 2025 from $10.045 million for H1 2024.
• Cash and cash equivalents significantly decreased to $25.922 million as of June 30, 2025, from $36.746 million at December 31, 2024.
• The company has an accumulated deficit of $310.9 million as of June 30, 2025, and has not generated product revenue to date.
• The Second Newsoara Amendment, which included a $20.0 million upfront global rights fee, became null and void as Newsoara did not pay the fees by June 26, 2025.
• No shares were sold under the TD Cowen ATM Offering during Q2 2025 or H1 2025, despite having $47.5 million available.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to a history of net losses and negative cash flows from operations.
• The need for significant additional capital to fund ongoing operations and future clinical trials, with no assurance that such funding will be available on acceptable terms or at all.
• Failure to raise additional capital could have a significant negative impact on financial condition.
• The successful development of drug candidates is highly uncertain, with numerous risks associated with clinical trials, regulatory approvals, and commercialization.
• Potential for significant additional financial resources and time if the FDA or other regulatory authorities require additional clinical trials or if enrollment delays occur.
• The company has not generated any revenue from drug sales and does not expect to until regulatory approval and commercialization of drug candidates.
• Future capital requirements are dependent on many factors, including the progress and costs of trials, regulatory approvals, and intellectual property defense.
• Raising additional capital through equity or convertible debt could dilute ownership interests of common stockholders.
• Debt or preferred equity financing may involve restrictive covenants.
• Collaborations or licensing arrangements may require relinquishing valuable rights or granting unfavorable licenses.

Future Outlook

The company expects to continue incurring significant research and development expenses as it advances cadisegliatin and other drug candidates. Top-line data from the Phase 3 CATT1 study for Type 1 diabetes is anticipated in the second half of 2026. A food effect study for cadisegliatin in healthy volunteers is expected to be completed by the end of 2025. Further registrational studies for cadisegliatin in Type 1 diabetes are expected to commence in 2027. A Phase 2 trial for cadisegliatin in Type 2 diabetes, in partnership with G42, is expected to begin in the fourth quarter of 2025. The company continues to evaluate financing strategies, including direct equity investments and potential licensing, to fund future operations and clinical trials.

Management Comments

• "We are a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases."
• "The Company continues to advance the [CATT1] trial and expects to have top line data from the trial in the second half of 2026."
• "We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized."
• "We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of cadisegliatin and further advance the development of our other drug candidates, subject to the availability of additional funding."
• "If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. As such, these conditions raise substantial doubt about the Company’s ability to continue as a going concern."
• "We continue to evaluate financing strategies to fund future clinical trials of cadisegliatin, including direct equity investments and the potential licensing and monetization of other Company programs."

Industry Context

vTv Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting diabetes and other chronic diseases. Its lead candidate, cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator, aims to address a significant unmet need in Type 1 diabetes as an adjunctive therapy to insulin. The FDA's Breakthrough Therapy designation highlights the potential of cadisegliatin, offering a faster development pathway. The company's strategy to pursue both Type 1 and Type 2 diabetes indications, including a partnership with G42 for a Phase 2 trial in Type 2 diabetes, aligns with the growing global burden of diabetes and the demand for novel therapeutic approaches. The allowance of new patent claims strengthens its competitive position in intellectual property. However, like many clinical-stage biotechs, vTv faces significant financial challenges, including a history of losses and a reliance on external funding, which is common in an industry where product commercialization is distant and uncertain.

Comparison to Industry Standards

• The Breakthrough Therapy designation for cadisegliatin in Type 1 Diabetes is a significant positive, as it indicates the FDA believes the drug may offer substantial improvement over existing therapies for a serious condition. This is a competitive advantage compared to companies without such designations.
• The company's focus on a "first-in-class oral liver-selective glucokinase activator" (cadisegliatin) positions it in a niche within the diabetes market, potentially offering a differentiated mechanism of action compared to established drug classes like GLP-1 agonists (e.g., Ozempic, Wegovy from Novo Nordisk, Mounjaro from Eli Lilly) or SGLT2 inhibitors (e.g., Jardiance from Eli Lilly/Boehringer Ingelheim, Farxiga from AstraZeneca).
• The Phase 3 CATT1 trial's primary endpoint focusing on reducing Level 2 and Level 3 hypoglycemia is consistent with recent FDA draft guidance (May 2023), indicating an adaptive approach to regulatory expectations. This is a critical alignment for a T1D adjunctive therapy, as hypoglycemia is a major concern for patients.
• The partnership with G42 Investments for a Phase 2 trial in Type 2 Diabetes in the Middle East demonstrates a strategy to expand market reach and share development costs, a common practice for smaller biotechs seeking to de-risk programs and access new markets.
• The company's financial position, with an accumulated deficit of over $310 million and a "going concern" warning, is typical for clinical-stage biopharmaceutical companies that have not yet commercialized a product. Many peers in this stage operate at a loss and rely heavily on capital raises. The $25.9 million cash balance is relatively low for a company with an ongoing Phase 3 trial, suggesting a more urgent need for additional financing compared to some better-capitalized peers.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• MacAndrews & Forbes Incorporated (MacAndrews) directly or indirectly controls 577,108 shares of Class B common stock and holds 912,982 shares of Class A common stock, representing approximately 46.6% of the combined voting power.
• The company is party to a Tax Receivable Agreement with M&F TTP Holdings Two LLC, which provides for payment of 85% of cash savings in U.S. federal, state, and local income tax realized from the exchange of Class B common stock and vTv Units for Class A common stock. No liability recognized as no exchanges have occurred.
• Letter Agreements with MacAndrews for the right to sell/require sale of Class A common stock have expired.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity raises due to ongoing funding needs. The "going concern" warning indicates substantial risk to investment. The reinitiation of the Phase 3 trial and positive patent news could provide long-term value if successful, but short-term financial performance is concerning.
• Employees: Continued operations and clinical trial progress provide job stability, but the company's financial challenges and need for further funding could create uncertainty.
• Customers (future): Successful development of cadisegliatin could offer a new treatment option for diabetes patients, particularly those with Type 1 diabetes, addressing an unmet medical need.
• Creditors: The "going concern" warning and accumulated deficit indicate increased risk for current and potential creditors.
• Suppliers/Partners: Continued R&D spending benefits suppliers of clinical trial services and materials. The partnership with G42 is progressing, but the failed Newsoara upfront payment highlights risks in collaboration agreements.

Next Steps

• Complete the food effect study in healthy volunteers by the end of 2025.
• Initiate a double-blind, randomized, controlled Phase 2 trial for cadisegliatin in Type 2 diabetes with G42 in the Middle East region in the fourth quarter of 2025.
• Obtain top-line data from the Phase 3 CATT1 study in the second half of 2026.
• Start further registrational studies for cadisegliatin in Type 1 diabetes in 2027.
• Continue to evaluate and pursue financing strategies, including direct equity investments and potential licensing/monetization of other programs.

Key Dates

Recommendation

The company faces severe liquidity challenges, evidenced by a significant cash burn, an accumulated deficit exceeding $310 million, and a "going concern" warning. While the reinitiation of the Phase 3 CATT1 trial for cadisegliatin and a new patent allowance are positive clinical developments, they are overshadowed by the immediate financial instability and the failure to secure a $20 million upfront payment from a collaboration. The reliance on future capital raises, with no certainty of success or favorable terms, presents substantial risk. For a seasoned investor, the current financial state suggests a high probability of further dilution and potential for significant capital loss, making it an unfavorable investment at this time.

Keywords

vTv Therapeutics, cadisegliatin, Type 1 Diabetes, T1D, Phase 3 trial, CATT1, glucokinase activator, GKA, biopharmaceutical, clinical stage, SEC filing, 10-Q, drug development, Breakthrough Therapy, clinical hold, financial results, liquidity, biotech